Navigation Links
Therapeutic Cloning Works in Mice With Parkinson's
Date:3/24/2008

Injecting neurons that were genetic match improved symptoms, avoided rejection

MONDAY, March 24 (HealthDay News) -- Therapeutic cloning successfully treated Parkinson's disease in mice, researchers report.

Using the process to develop dopamine-producing neurons with an identical genetic profile to each mouse being treated allowed scientists to significantly improve the neurological performance of the diseased animals, without provoking any evidence of immune system rejection.

"This is the first time that anyone has done this kind of cloning experiment to show the therapeutic aspect of the process in this customized way," said study author Dr. Viviane Tabar, an associate professor of neurosurgery in the department of neurosurgery at the Memorial Sloan-Kettering Cancer Center in New York City.

The finding -- which has not yet been replicated in human trials -- was published in the March 23 online issue of Nature Medicine.

Parkinson's is a neurodegenerative disorder that severely impairs motor skills and speech. According to the National Parkinson Foundation, 1.5 million Americans suffer from the disease, and men and women over 65 are at the greatest risk of developing the debilitating condition.

The illness is sparked by the breakdown of nerve cells in the brain and a resulting drop in the production of the dopamine -- a chemical key to the proper function of muscles and movement. In recent years, the effort to slow or halt dopamine loss has focused on the promise of therapeutic cloning.

Controversy over the ethical ramifications of cloning has led many researchers to draw a clear distinction between therapeutic cloning and reproductive cloning.

Both processes begin with the removal of the nucleus from a single cell taken from any part of the body of a living adult organism. In the laboratory, this isolated nucleus is then inserted into an egg cell that has been stripped
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. AUDIO from Medialink and Commit Lozenge: Wanna Quit Smoking With Therapeutic Nicotine? Just Follow the Directions
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Therapeutic Cloning Works in Mice With Parkinson's
(Date:5/23/2013)... THURSDAY, May 23 (HealthDay News) -- A modified ... help fight brain tumors, preliminary research suggests. ... investigational therapy, known as PVSRIPO, uses an engineered ... normal cells, but attacks cancer cells. The therapy ... most common and aggressive brain tumor, they said. ...
(Date:5/23/2013)... when a woman harried by hot flashes says she,s ... published online in Menopause , the journal of ... objective tests that what these women say about their ... showed that hot flashes were related to memory problems, ... there was a relationship between hot flashes and what ...
(Date:5/23/2013)... Williamsport, PA (PRWEB) May 23, 2013 ... Sitter® Teaching Site, offering a comprehensive babysitting training course ... nationally-recognized program was developed by Indianapolis pediatrician Dr. Patricia ... in the care of an adult sitter who didn’t ... a well-rounded youth development program with a medical basis ...
(Date:5/23/2013)... drug about to be tested in a clinical trial ... treatment for Alzheimer,s disease has failed to work with ... patients, according to results of a study by University ... of neuroscience affiliated with the Evelyn F. and William ... emphasized the importance of verifying promising research results before ...
(Date:5/23/2013)... 2013 The Rottenstein Law Group LLP, ... created the Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol ... and those who are considering filing lawsuits. , ... cause severe liver damage, according to a 2009 report ... the “safety communication,” the FDA warned consumers against using ...
Breaking Medicine News(10 mins):Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2
... School of Medicine have identified proteins in the rod and ... of the genetic causes of a host of inherited ... of what goes wrong at the most basic level in ... ,Specifically, they have identified and measured the types and amounts ...
... established a Scientific Advisory Board for its transplantation ... of its United States (U.S.) clinical development ... and Larry Chodoff LifeCycle Pharma A/S OMX:LCP) today ... Board (SAB) of experts in the field of ...
... Autistic children are invariably heavier than others. Researchers ... for Disease Control and Prevention and the Cincinnati ... be contributing to such a phenomenon. ,Other studies ... rapid head growth in early life. ,However, ...
... women graduating as doctors from Medical school than men. In a ... that 58% of doctors graduating from UK medical schools in ... pursuing a career as a doctor outnumber men by almost three ... five female doctors anticipate working part-time for most of their career. ...
... There were a lot of red faces among Texan lawmakers ... twice honored as the "doctor of the day," was ... with a 17-year-old. ,The "doctor of the day" is ... public with medical needs. ,Dr. Nilon Tallant, 75, ...
... Rutgers University study has claimed that being employed on ... cause both depression and anxiety. ,According toChester ... School of Business-Camden, the lunar settlements of tomorrow - ... - carry long-term implications for the mental health of ...
Cached Medicine News:Health News:Genetic Cause of Inherited Eye Diseases Identified 2Health News:LifeCycle Pharma Forms Scientific Advisory Board in Solid Organ Transplantation 2Health News:Autism Could Be Related to Higher Level of Growth Hormones 2Health News:More Women Medical Graduates Than Men 2Health News:Sex Offender Honored Twice by Texan Lawmakers 2
(Date:5/23/2013)... -- BioElectronics Corporation (OTC Pink: BIEL), the maker of very ... panel meeting for non-thermal shortwave diathermy: The ... Meeting was held on May 21, 2013 in ... the meeting was very narrow, in that the FDA ... application of non-thermal shortwave diathermy for the treatment of ...
(Date:5/23/2013)... May 23, 2013 Halozyme Therapeutics, Inc. ... appointment of David A. Ramsay ... most recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and ... working in our commercial group for the last ...
(Date:5/23/2013)... CARLSBAD, Calif. , May 23, 2013 Isis ... antisense therapeutics, today announced that management will present a company ... Health Care Conference on Thursday, May 30, 2013 at 8:40 ... A live audio webcast of the presentation will be ... Web site, www.isispharm.com .  A replay will be available ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2
... Resources, one of the world,s leading research and ... that the increased generic erosion of key drugs ... (Abbott/Sanofi-Aventis,s Depakote/Abbott,s Depakote ER, generics), combined with projected ... will cause a precipitous $2.3 billion decline in ...
... Aug. 25 Actelion Pharmaceuticals US, Inc., today ... (FDA) has approved the brand name VELETRI® for the ... available since April 2010 as Epoprostenol for Injection for ... (PAH) and PAH associated with the scleroderma spectrum of ...
Cached Medicine Technology:Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market 2Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI® (epoprostenol for injection) for Pulmonary Arterial Hypertension 2Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI® (epoprostenol for injection) for Pulmonary Arterial Hypertension 3Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI® (epoprostenol for injection) for Pulmonary Arterial Hypertension 4
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 8.7 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 15 mm....
Medicine Products: